From: PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
Luminal A | Luminal B | HER2-E | Basal-like | |
---|---|---|---|---|
ER+/PR+/HER2- (n = 471) | 244 (52%) | 170 (36%) | 53 (11%) | 4 (1%) |
ESR1+/PGR+/ERBB2- (n = 397) | 239 (60%) | 127 (32%) | 31 (8%) | 0 (0%) |
ER+/PR-/HER2- (n = 81) | 12 (15%) | 47 (58%) | 19 (23%) | 3 (4%) |
ESR1+/PGR-/ERBB2- (n = 101) | 15 (15%) | 65 (64%) | 18 (18%) | 3 (3%) |
ER-/PR-/HER2+ (n = 39) | 0 (0%) | 7 (18%) | 30 (77%) | 2 (5%) |
ESR1-/PGR-/ERBB2+ (n = 51) | 0 (0%) | 6 (12%) | 41 (80%) | 4 (8%) |
ER-/PR-/HER2- (n = 101) | 4 (4%) | 10 (10%) | 30 (30%) | 57 (56%) |
ESR1-/PGR-/ERBB2- (n = 90) | 0 (0%) | 2 (2%) | 28 (31%) | 60 (67%) |
ER+/PR+/HER2+ (n = 45) | 2 (4%) | 18 (40%) | 25 (56%) | 0 (0%) |
ESR1+/PGR+/ERBB2+ (n = 80) | 23 (29%) | 33 (41%) | 24 (30% | 0 (0%) |
ER+/PR-/HER2+ (n = 18) | 0 (0%) | 4 (22%) | 14 (78%) | 0 (0%) |
ESR1+/PGR-/ERBB2+ (n = 53) | 0 (0%) | 28 (53%) | 25 (47%) | 0 (0%) |
ER-/PR+/HER2- (n = 25) | 14 (56%) | 4 (16%) | 3 (12%) | 4 (16%) |
ESR1-/PGR+/ERBB2- (n = 7) | 0 (0%) | 0 (0%) | 4 (57%) | 3 (43%) |
ER-/PR+/HER2+ (n = 2) | 1 (50%) | 1 (50%) | 0 (0%) | 0 (0%) |
ESR1-/PGR+/ERBB2+ (n = 3) | 0 (0%) | 0 (0%) | 3 (100%) | 0 (0%) |